Zafgen, Inc. (ZFGN) Downgraded by Zacks Investment Research
Zacks Investment Research lowered shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report report published on Saturday morning.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine lowered Zafgen from a sell rating to a strong sell rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $6.50.
Zafgen (ZFGN) opened at 3.40 on Friday. Zafgen has a 12 month low of $2.89 and a 12 month high of $5.46. The stock’s market capitalization is $93.44 million. The stock’s 50 day moving average is $3.46 and its 200-day moving average is $4.00.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same period last year, the business earned ($0.55) EPS. On average, equities research analysts expect that Zafgen will post ($2.23) earnings per share for the current year.
WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/13/zafgen-inc-zfgn-downgraded-by-zacks-investment-research-2.html.
In related news, insider Dennis D. Kim acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The stock was purchased at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the purchase, the insider now directly owns 21,443 shares in the company, valued at $72,691.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 21.20% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of ZFGN. Algert Global LLC bought a new position in Zafgen during the 2nd quarter worth $123,000. Parametric Portfolio Associates LLC grew its stake in Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 10,327 shares during the last quarter. Nine Chapters Capital Management LLC bought a new position in Zafgen during the 1st quarter worth $170,000. Wells Fargo & Company MN grew its stake in Zafgen by 1,290.3% during the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in Zafgen during the 2nd quarter worth $259,000. Hedge funds and other institutional investors own 48.52% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.